Lani,
Just recieved this blurb tonight...FYI..
This company, Apthera, has a breast cancer vaccine called neuvax to help prevent cancer recurrence if you're HER2-positive. The phase II clinical trial results are posted on their website stating, "At this point, clinical recurrence rates at 24 months are 5.6% (5/90) for vaccinated patients versus 14.8% (12/81) for the observation group (p=0.04)." The vaccine was originally developed at MD Anderson.
The treatment is going to start phase III trials this year... Their website is:
www.apthera.com.
When you have a minute please review, Thanks for all your research!
Marcia